-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
The China Drug Clinical Trial Registration and Information Disclosure Platform shows that Yibaikang Pharmaceutical, a subsidiary of Eteng Jingang, has launched a phase 2 clinical study in China to evaluate recombinant human lymphocyte activation gene-3 (hLAG-3) fusion protein The safety and efficacy of (EOC202) injection combined with albumin paclitaxel in advanced breast cancer patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative endocrine therapy
Public information shows that EOC202 (eftilagimod alpha) is one of Immutep’s main research therapies.
LAG-3 is an immune checkpoint protein expressed on the surface of effector T cells and regulatory T cells (Tregs)
Public information shows that EOC202 is a soluble LAG-3 fusion protein
According to the public information of Eton King Ang, as a tumor immune activation drug, EOC202 is differentiated in tumor immunotherapy combined with chemotherapeutic drugs: chemotherapeutic drugs will kill most tumor cells, and then the immunotherapy drug EOC202 will improve immunity and improve immunity.
Prior to this, Immutep had carried out a global phase 2 clinical trial of EOC202 in combination with the PD-1 inhibitor Keytruda in different indications, and achieved good results
In China, the results of a phase 1 clinical trial of EOC202 combined with the chemotherapy drug paclitaxel in the treatment of metastatic breast cancer showed that the safety evaluation results of the combination therapy were generally tolerable, and there were no serious untreated adverse reactions during the safety evaluation period
The launch of EOC202 in China is a phase 2 clinical study on the safety and efficacy of combined albumin paclitaxel in advanced breast cancer patients with advanced HR-positive and HER2-negative endocrine therapy
Currently, chemotherapy is still one of the main treatment options for metastatic breast cancer.
Reference materials:
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
